top of page

Paris based Coave Therapeutics is conjugating ligands onto vector surfaces to improve targeting and delivery - it is attracting partner and investor interest

  • Sep 5, 2024
  • 1 min read

CEO Rodolphe Clerval describes the scientific rationale, and how Coave has engineered this to be easy to add at the end of vector manufacturing. Plus, he shares an update on the company's fundraising, partnering, and wholly owned programs.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page